Optimizing Management Beyond Triple Therapy in Stable Severe Chronic Obstructive Pulmonary Disease: Efficacy of Adjunctive Oral Doxophylline in a Randomized Controlled Trial

Adjunctive oral doxophylline significantly improved symptom burden and systemic inflammation in patients with stable severe COPD without conferring additional spirometric benefits. Although mild adverse effects were observed, doxophylline was overall well tolerated and may represent a viable adjunctive option in selected COPD patients with persistent symptoms despite optimized inhaler therapy.